Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Jan 28 2010Anacor Pharmaceuticals

Anacor Pharmaceuticals announced today that it will present a poster and oral presentation on a novel systemic anti-inflammatory candidate, AN6415, at the upcoming 8th Cytokines and Inflammation Conference, taking place January 28-29, 2010 in La Jolla, California.

Title: AN6415: A Novel, Highly Potent PDE4 Inhibitor with Oral Activity and Broad Spectrum Cytokine Suppression

  • Poster Presentation: Thursday, January 28 from 5:00 to 6:30pm.
  • Oral Presentation: Friday, January 29 at 1:00pm
Source:

Anacor Pharmaceuticals

Posted in: Drug Trial News

Tags: , , , , ,

Comments (0)

Suggested Reading

Combined effect of poverty and inflammation on mortality is worse than expected from separate effects, study reports
Study reveals inflammation's role in long COVID's lingering effects
SARS-CoV-2 fragments found to mimic immune system peptides, fueling inflammation
Study reveals how SARS-CoV-2 hijacks lung cells to drive COVID-19 severity
New study sheds light on sex differences in allergic airway inflammation
How does social adversity influence biomarkers of stress and inflammation in children?
Vitamin D deficiency persists despite easy access, review suggests need for tailored supplements
US study links extended sitting and lack of coffee to higher death rates

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Interventions for mood show promise for the management of IBD in improving mental health, inflammation and disease outcomes